Summit Therapeutics Inc. (SMMT) stock
SMMTNasdaqPharmaceutical PreparationsFiscal year ends December 31
$10.67−1.15 (-9.73%)
Close on Nov 17, 2026Market cap $8.51BP/E –Yield –
Summit Therapeutics profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Summit Therapeutics's profit margin for the twelve months ending Jun 30, 2023 was -271685.0%. For fiscal 2022 it was -11174.8%, against -4897.8% the year before.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | -11174.8% | −6276.9 |
| FY2021 | Dec 31, 2021 | -4897.8% | −4916.9 |
| FY2019 | Jan 31, 2019 | 19.0% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2022CQ3 2022 | Sep 30, 2022 | -9720.5% | −8223.2 |
| Q2 FY2022CQ2 2022 | Jun 30, 2022 | -7136.6% | +35698.5 |
| Q1 FY2022CQ1 2022 | Mar 31, 2022 | -8558.8% | +549.5 |
| Q4 FY2021CQ4 2021 | Dec 31, 2021 | -10796.4% | – |
| Q3 FY2021CQ3 2021 | Sep 30, 2021 | -1497.2% | – |
| Q2 FY2021CQ2 2021 | Jun 30, 2021 | -42835.1% | – |
| Q1 FY2021CQ1 2021 | Mar 31, 2021 | -9108.3% | – |
See a number that looks wrong?